Izeltabart Biosimilar - Research Grade

Human

ADAM9

>1mg/ml

IgG1 - kappa

CHO Cells

https://www.imgt.org/mAb-DB/

ICH3002

Q13443

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of the originator antibody izeltabart (the antibody component of izeltabart tapatansine / IMGC936), an investigational anti-ADAM9 agent. It is a human IgG1-kappa recombinant protein built around the ADAM9 target, supplied for research use only (RUO) and not intended for human or veterinary use. Because it is provided unconjugated and payload-free, it serves as a defined tool for studying ADAM9 engagement independent of any cytotoxic warhead. Typical research applications include use as a binding reagent, an isotype-matched positive control, a naked-antibody comparator in antibody-drug conjugate (ADC) development workflows, and a standard in target-expression and internalization assays. The material is offered at research grade with low endotoxin (<1 EU/mg; ultra-low <0.5 EU/mg options), and is available in bulk milligram-to-gram quantities to support scale-dependent in-vitro and preclinical studies. As a biosimilar analog it reproduces the target specificity of the originator for experimental purposes rather than replicating any clinical formulation. ADAM9 (Q13443; ADAM metallopeptidase domain 9) is a type I transmembrane member of the ADAM (a disintegrin and metalloproteinase) family. It combines a catalytic metalloprotease domain, mediating ectodomain shedding of numerous cell-surface substrates, with a disintegrin domain that supports integrin-dependent cell adhesion. Through these activities ADAM9 participates in cell-cell and cell-matrix interactions, motility, and proteolytic release of membrane proteins involved in tumorigenesis and angiogenesis, including reported substrates such as EPHB4, KDR/VEGFR2, TEK, CD40, VCAM1 and CDH5. ADAM9 is overexpressed across several solid tumor types and its expression often correlates with invasiveness and poorer prognosis, making it a tumor-associated antigen of interest for targeted therapeutics. Germline loss-of-function variants in ADAM9 are associated with inherited retinal dystrophies, underscoring physiological roles beyond cancer.

Cellular disintegrin-related protein, Meltrin-gamma, Metalloprotease/disintegrin/cysteine-rich protein 9, Myeloma cell metalloproteinase, Disintegrin and metalloproteinase domain-containing protein 9, MCMP, MDC9, MLTNG

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks

Q: Is the Izeltabart biosimilar available in bulk mg to gram quantities?

A: Yes — it is manufactured in scalable milligram to gram quantities for high-throughput and bulk in vivo experiments.

Q: Is this research-grade Izeltabart biosimilar suitable for in vivo use?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Izeltabart biosimilar target?

A: It is an unconjugated, non-therapeutic analog of Izeltabart that binds ADAM9; for research use only.